Vera Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q4 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Vera Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q4 2024.
Vera Therapeutics, Inc. Debt-to-equity for the quarter ending December 31, 2024 was 19 %, a 57.3% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q4 2024	19	-25.4	-57.3%	Dec 31, 2024
Q3 2024	26.9	-15.8	-37%	Sep 30, 2024
Q2 2024	28.8	-10.1	-25.9%	Jun 30, 2024
Q1 2024	34.2	-0.28	-0.81%	Mar 31, 2024
Q4 2023	44.4	+12.9	+41%	Dec 31, 2023
Q3 2023	42.7	+20.1	+88.6%	Sep 30, 2023
Q2 2023	38.8	+19.9	+105%	Jun 30, 2023
Q1 2023	34.5	+19.9	+136%	Mar 31, 2023
Q4 2022	31.5	+11.4	+56.7%	Dec 31, 2022
Q3 2022	22.6	+441		Sep 30, 2022
Q2 2022	18.9			Jun 30, 2022
Q1 2022	14.6			Mar 31, 2022
Q4 2021	20.1			Dec 31, 2021
Q3 2021	-419			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.